Analysis of Innate Immune Competence in People With Chronic Obstructive Pulmonary Disease (COPD)

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Procedure
Study Type: Observational
SUMMARY

Chronic Obstructive Pulmonary Disease (COPD) causes obstruction to airflow when breathing out. It is a leading cause of chronic lung disease, hospitalization and death. Smoking is the major cause of COPD but why some smokers develop COPD while others do not is poorly understood. A central feature of COPD is accumulation of inflammatory blood cells, macrophages and neutrophils, in the airway, leading to lung injury and airway damage. The small airways of many patients with COPD contain bacteria, which are absent in healthy smokers or non-smokers. These bacteria stimulate recruitment of neutrophils, macrophages and other inflammatory cells, further accelerating airway injury. The investigators and others have shown resident macrophages in the lung and inflammatory cells (neutrophils and macrophages) recruited from the blood, which normally clear bacteria, have reduced anti-bacterial capacity in COPD and that their altered function impairs the resolution of inflammation. The investigators now wish to test why these cells fail to clear bacteria focusing in particular on how they use molecules as food to generate energy, a process termed metabolism, since this is an important determinant of immune cell function. Comparison will be made between lung resident cells (obtained by performing bronchoscopy and washing a segment of lung to flush out immune cells) and those from the blood to determine if the alterations are specific to the lung. The investigators will identify alterations in responses to bacteria in relation to changes in metabolism . A major focus will be on how structures in the cell that normally are key for energy production (i.e. mitochondria) become dysfunctional and how this impacts responses to bacteria. The investigators will relate findings to the clinical features of COPD and to healthy non-smokers and smokers to separate smoking-related changes from COPD. The aim is to develop new approaches with which to treat and manage COPD.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 77
Healthy Volunteers: t
View:

⁃ COPD patients:

• COPD patients aged 18-77 years who are GOLD Stage 1 or 2 or 3; for patients undergoing bronchoscopy already for a clinical reason.

• COPD patients aged 18-77 years old who are GOLD Stage 1,2 or 3 for patients who are donating blood only.

• COPD patients aged 18-69 years who are GOLD Stage 1 or 2 for patients undergoing bronchoscopy for research purposes.

• COPD- Defined by radiological investigation of chest either chest X-ray or High-resolution CT scan in previous 12 months

• Ability to provide informed consent

⁃ Healthy volunteers:

• Any healthy volunteer aged 18-77 years

• Ability to provide informed consent

Locations
Other Locations
United Kingdom
Royal Infirmary of Edinburgh
RECRUITING
Edinburgh
University of Edinburgh
NOT_YET_RECRUITING
Edinburgh
Contact Information
Primary
David H Dockrell, MD
David.Dockrell@ed.ac.uk
+441312426213
Backup
Sarah Walmsley, MD
Sarah.Walmsley@ed.ac.uk
Time Frame
Start Date: 2023-05-11
Estimated Completion Date: 2028-02-10
Participants
Target number of participants: 189
Treatments
COPD patients
Bronchoscopy to retrieve bronchoalveolar lavage fluid for isolation of immune cells, and phlebotomy for blood sample collection.
Healthy controls - smokers
Bronchoscopy to retrieve bronchoalveolar lavage fluid for isolation of immune cells, and phlebotomy for blood sample collection.
Healthy controls - non-smokers
Bronchoscopy to retrieve bronchoalveolar lavage fluid for isolation of immune cells, and phlebotomy for blood sample collection.
Sponsors
Leads: University of Edinburgh

This content was sourced from clinicaltrials.gov